APPROVED_FOR_MARKETINGNot Applicable

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

United States

Plain-language summary

An open-label, single-arm, multi-centre program providing treatment access to ALGS patients with cholestatic pruritus in the US. Access can be requested through Clinigen Healthcare Ltd via email MirumALGS@clinigengroup.com or telephone +1-877-768-4303.

Who can participate

Age range12 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Informed consent and assent provided, as applicable, per Institutional Review Board (IRB) or Ethics Committee (EC)
✓. Clinical and/or genetic diagnosis of ALGS
✓. Male or female participants aged \>12 months and ≥5 kg with clinically significant cholestatic pruritus associated with ALGS
✓. Willingness to adhere to an acceptable method of contraception until treatment discontinuation by females of childbearing potential who are sexually active or who become sexually active during the program
✓. No other therapeutic options or access to any ongoing ALGS clinical trials

Exclusion criteria

✕. Diagnosis with a cholestatic liver disease other than ALGS
✕. Female who is pregnant or breastfeeding
✕. Clinically significant cardiovascular, hepatic, gastro-intestinal, pulmonary, neurologic, infectious or renal disease or other medical condition that, in the opinion of the physician or Medical Monitor, would preclude participation in the program
✕. Past medical history of compensated or decompensated cirrhosis
✕. Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of maralixibat or its mode of action

Trial details

NCT IDNCT04530994

SponsorMirum Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Alagille Syndrome trials